Evidence map›Paper›PMID 38978807›Full record

ArticleAging biology2023

Aging, Parkinson's Disease, and Models: What Are the Challenges?

Emily Rocha, Manish Chamoli, Shankar J Chinta, Julie K Andersen, Ruby Wallis, Erwan Bezard, Matt Goldberg, Tim Greenamyre, Warren Hirst, We-Li Kuan and 10 more

Abstract read
In one paragraph

Article in Aging biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Emily RochaPittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Manish ChamoliBuck Institute for Research on Aging, Novato, CA, USA.
Shankar J ChintaBuck Institute for Research on Aging, Novato, CA, USA.
Julie K AndersenBuck Institute for Research on Aging, Novato, CA, USA.
Ruby WallisThe Healthy Lifespan Institute, Sheffield, United Kingdom.
Erwan BezardUniversity of Bordeaux, Bordeaux, France.
Matt GoldbergThe University of Alabama, Birmingham, AL, USA.
Tim GreenamyrePittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Warren HirstBiogen, Cambridge, MA, USA.
We-Li KuanDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Deniz KirikBrain Repair and Imaging in Neural Systems (BRAINS), Lund, Sweden.
Laura NiedernhoferInstitute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA.
Irit RappleyRecursion pharmaceuticals, Salt Lake City, UT, USA.
Shalini PadmanabhanThe Michael J. Fox Foundation for Parkinson's Disease, New York, NY, USA.
Louis-Eric TrudeauDepartment of pharmacology and physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Maria SpillantiniClinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Simon ScottCure Parkinson's, London, United Kingdom.
Lorenz StuderThe Center for Stem Cell Biology and Developmental Biology Program, Sloan-Kettering Institute for Cancer Research, New York, NY, USA.
Ilaria BellantuonoThe Healthy Lifespan Institute, Sheffield, United Kingdom.
Heather MortiboysThe Healthy Lifespan Institute, Sheffield, United Kingdom.

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents ADRF1AG062280 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI ANDERSEN, JULIE KAY · 2018 to 2022
$3.9M
Neuronal FXR as a potential therapeutic target for Alzheimer's diseaseR01AG067325 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI ANDERSEN, JULIE KAY, LITHGOW, GORDON J · 2020 to 2024
$3.1M
A temporal bioenergetic, metabolomics, and proteomic map of Alzheimer's disease in invertebrate modelsRF1AG057358 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI ANDERSEN, JULIE KAY, LITHGOW, GORDON J · 2017 to 2017
$3.0M
NIA NIH HHS P30 AG024827NIA NIH HHS R01 AG067325NIA NIH HHS RF1 AG057358NIA NIH HHS RF1 AG062280
6 · The paper itself

Abstract

Parkinson's disease (PD) is a chronic, neurodegenerative condition characterized by motor symptoms such as bradykinesia, rigidity, and tremor, alongside multiple nonmotor symptoms. The appearance of motor symptoms is linked to progressive dopaminergic neuron loss within the substantia nigra. PD incidence increases sharply with age, suggesting a strong association between mechanisms driving biological aging and the development and progression of PD. However, the role of aging in the pathogenesis of PD remains understudied. Numerous models of PD, including cell models, toxin-induced models, and genetic models in rodents and nonhuman primates (NHPs), reproduce different aspects of PD, but preclinical studies of PD rarely incorporate age as a factor. Studies using patient neurons derived from stem cells via reprogramming methods retain some aging features, but their characterization, particularly of aging markers and reproducibility of neuron type, is suboptimal. Investigation of age-related changes in PD using animal models indicates an association, but this is likely in conjunction with other disease drivers. The biggest barrier to drawing firm conclusions is that each model lacks full characterization and appropriate time-course assessments. There is a need to systematically investigate whether aging increases the susceptibility of mouse, rat, and NHP models to develop PD and understand the role of cell models. We propose that a significant investment in time and resources, together with the coordination and sharing of resources, knowledge, and data, is required to accelerate progress in understanding the role of biological aging in PD development and improve the reliability of models to test interventions.

Identifiers

PMID38978807
PMCPMC11230631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.